Jamie Gregory: No. No. No. I am saying that what was not in the prior guide is the 1% impact of Qualpay. The other growth initiatives were in the guidance in January, as well as the guide in April. But what I would say on the growth initiatives is those initiatives have been trim down a little bit individually and in various ways as we progress through this environment. And so the spend on both Maast and CIB is a little bit less than what we guided to in January, but the only change in those spends from April was really just the Qualpay addition.
Kevin Fitzsimmons: Understood. Okay. And one quick follow-on, I think, it — some banks are talking about or that they are evaluating potential bond transactions where you would take some kind of upfront loss, but then we would be able to put those proceeds to work at higher rates and/or paydown debt. I would suspect that, with your goal of getting to the 10% CET1, maybe that’s not something that’s near-term so you get to that point, but is that something you guys are evaluating and over what timeframe? Thanks.
Jamie Gregory: It’s a great question. As we look at our bond portfolio, first off, in aggregate, the duration and the payback is too long to consider transaction like that. And you are right and you can see this through our MOB transaction. It’s our intent to accrete capital at the moment. We remain really excited about with the opportunity that’s in front of us in the Southeast to drive client growth and that’s our highest and best use of capital and so we are not that interested in realizing a loss in the securities portfolio to mark the yield to market at the moment.
Kevin Fitzsimmons: Okay. Thanks very much.
Operator: Our next question comes from the line of Jared Shaw with Wells Fargo. Jared, please go ahead. Your line is now open.
Jared Shaw: Hey. Good morning. Thanks.
Kevin Blair: Hi, Jared.
Jared Shaw: Just following up on the loan sales that the participations in the medical office. Is that the end of loan sales at this point and what are the uses of from the proceeds there? Should we just assume that the that wholesale FHLB has paid down or what’s the use of fund there?
Jamie Gregory: We are not anticipating further loan sales. Truthfully, that’s not something that we would anticipate in normal course of business outside of the third-party portfolio. Typically, in — especially in an environment like this, the best course of action for a business that may have a lower return than what you are targeting would be just to let it a trite and that would be a normal course of business is let the loans pay off at par and move on and pre-up the balance sheet that way and that’s the traditional way to exit a high performing business like the medical office. That was just a unique one that the credit quality was so pristine that we were able to get what we believe was a very fair price for that portfolio. And with regards to the use of funds, you are right, it will go to paydown just more expensive funding, whether that’s FHLB or broker deposits, it will likely be one of those two.
Jared Shaw: And that $25 million that you called out, that’s net of the paydowns or that’s just the $25 million hit from losing the loans and then we can see an offset on the fund there?
Kevin Blair: Mark.
Jamie Gregory: That’s the mark. That’s the price mark effectively on the loan sale.
